主要文件

查看所有文档

SML2848

尼达尼布

Name: 尼达尼布
Brand: SIGMA

≥98% (HPLC), powder, VEGFR, PDGFR and FGFR inhibitor

别名:

(3Z)-2,3-二氢-3-[[[4-[甲基[2-(4-甲基-1-哌嗪基)乙酰基]氨基]苯基]氨基]苯基亚甲基]-2-氧代-1H-吲哚-6-羧酸甲酯, (Z)-3-(((4-(N-甲基-2-(4-甲基哌嗪-1-基)乙酰氨基)苯基)氨基)(苯基)亚甲基)-2-氧代二氢吲哚-6-羧酸甲脂, (Z)-3-[(4-{甲基-[2-(4-甲基哌嗪-1-基)乙酰基]氨基}苯基氨基)亚甲基]-2-氧代-2,3-二氢-1H-吲哚-6-羧酸甲酯, BIBF 1120, BIBF-1120, BIBF1120

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₃₁H₃₃N₅O₄

化学文摘社编号:

656247-17-5

分子量:

539.62

UNSPSC Code:

12352200

NACRES:

NA.77

MDL number:

MFCD11974012

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

尼达尼布, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C(NC1=C2)/C(C1=CC=C2C(OC)=O)=C(C3=CC=CC=C3)\NC4=CC=C(C=C4)N(C(CN5CCN(CC5)C)=O)C

InChI

1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-

InChI key

XZXHXSATPCNXJR-ZIADKAODSA-N

说明

Biochem/physiol Actions

口服活性，强效ATP竞争性VEGFR，FGFR，PDGFR，Flt3，Lck，Lyn，Src抑制剂，具有体内抗血管生成和抗纤维化功效。

尼达尼布（BIBF1120）是一种口服活性、强效ATP竞争性抑制剂，可抑制血管激酶VEGFR-1/2/3（IC₅₀ = 34/21/13 nM）、FGFR-1/2/3/4（IC₅₀ = 69/37/108/610 nM）、PDGFRα/β（IC₅₀ = 59/65 nM）以及Flt-3、Lck、Lyn和Src（分别为IC₅₀ = 26、16、195、156 nM），但不抑制33种其他激酶。尼达尼布在体内癌症和肺纤维化的培养物和动物模型中表现出抗血管生成和抗纤维化疗效。

pictograms

GHS06,GHS08,GHS05

signalword

Danger

hcodes

H301,H315,H318,H361fd,H372

pcodes

P202 - P260 - P280 - P301 + P310 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 3 Oral - Eye Dam. 1 - Repr. 2 - Skin Irrit. 2 - STOT RE 1

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Multi-kinase inhibitors and cisplatin for head and neck cancer treatment in vitro.

Roman C Brands et al.

Oncology letters, 18(3), 2220-2231 (2019-08-28)

Multidrug resistance (MDR) remains one of the major causes of suboptimal outcome following therapy in head and neck squamous cell carcinoma (HNSCC). ATP-binding cassette (ABC) transporters are overexpressed in HNSCC, which contributes to the limited effect of chemotherapeutic treatment. In

Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity.

Elaine Reguera-Nuñez et al.

Angiogenesis, 22(4), 535-546 (2019-08-30)

In contrast to VEGF pathway-targeting antibodies, antiangiogenic tyrosine kinase inhibitors (TKIs) have failed to meet primary endpoints in almost all phase III clinical trials when combined with conventional chemotherapy. One exception is the combination of nintedanib and docetaxel as a

Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).

Gerald J Roth et al.

Journal of medicinal chemistry, 52(14), 4466-4480 (2009-06-16)

Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a new treatment modality in oncology. Preclinical findings suggest that blockade of additional pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR

查看所有相关文献

全球贸易项目编号

货号	GTIN
SML2848-25MG	04061842374786
SML2848-5MG	04061842374793